Skip to main content
Erschienen in: Clinical and Translational Oncology 8/2019

14.01.2019 | Review Article

Time for radioimmunotherapy: an overview to bring improvements in clinical practice

verfasst von: O. Leaman Alcibar, D. Candini, F. López-Campos, M. Albert Antequera, V. Morillo Macías, A. J. Conde, A. Rodríguez Pérez, A. Hervás Morón, J. Contreras Martínez, C. Ferrer Albiach, S. Navarro Aguilar, M. E. Rodríguez-Ruiz

Erschienen in: Clinical and Translational Oncology | Ausgabe 8/2019

Einloggen, um Zugang zu erhalten

Abstract

Harnessing the patient’s own immune system against an established cancer has proven to be a successful strategy. Within the last years, several antibodies blocking critical “checkpoints” that control the activation of T cells, the immune cells able to kill cancer cells, have been approved for the use in patients with different tumours. Unfortunately, these cases remain a minority. Over the last years, radiotherapy has been reported as a means to turn a patient’s own tumour into an in situ vaccine and generate anti-tumour T cells in patients who lack sufficient anti-tumour immunity. Indeed, review data show that the strategy of blocking multiple selected immune inhibitory targets in combination with radiotherapy has the potential to unleash powerful anti-tumour responses and improve the outcome of metastatic solid tumours. Here, we review the principal tumours where research in this field has led to new knowledge and where radioimmunotherapy becomes a reality.
Literatur
1.
2.
Zurück zum Zitat Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011;480(7378):480–9.CrossRef Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011;480(7378):480–9.CrossRef
3.
Zurück zum Zitat Topalian SL, Weiner GJ, Pardoll DM. Cancer immunotherapy comes of age. J Clin Oncol. 2011;29(36):4828–36.CrossRef Topalian SL, Weiner GJ, Pardoll DM. Cancer immunotherapy comes of age. J Clin Oncol. 2011;29(36):4828–36.CrossRef
4.
Zurück zum Zitat Kfoury M, Disdero V, Vicier C, Le Saux O, Gougis P, Sajous C, et al. Immune checkpoints inhibitors: recent data from ASCO’s meeting 2017 and perspectives. Bull Cancer. 2018;105(7–8):686–95.CrossRef Kfoury M, Disdero V, Vicier C, Le Saux O, Gougis P, Sajous C, et al. Immune checkpoints inhibitors: recent data from ASCO’s meeting 2017 and perspectives. Bull Cancer. 2018;105(7–8):686–95.CrossRef
5.
Zurück zum Zitat Ehrlich P. Über den jetzigen Stand der Karzinomforschung. Ned Tijdschr Geneeskd. 1909;5:273–90. Ehrlich P. Über den jetzigen Stand der Karzinomforschung. Ned Tijdschr Geneeskd. 1909;5:273–90.
6.
Zurück zum Zitat Mole RH. Whole body irradiation; radiobiology or medicine? Br J Radiol. 1953;26(305):234–41.CrossRef Mole RH. Whole body irradiation; radiobiology or medicine? Br J Radiol. 1953;26(305):234–41.CrossRef
7.
Zurück zum Zitat Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39(1):1–10.CrossRef Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39(1):1–10.CrossRef
8.
Zurück zum Zitat Demaria S, Golden EB, Formenti SC. Role of local radiation therapy in cancer immunotherapy. JAMA Oncol. 2015;1(9):1325–32.CrossRef Demaria S, Golden EB, Formenti SC. Role of local radiation therapy in cancer immunotherapy. JAMA Oncol. 2015;1(9):1325–32.CrossRef
9.
Zurück zum Zitat Wennerberg E, Lhuillier C, Vanpouille-Box C, Pilones KA, García-Martínez E, et al. Barriers to radiation-induced in situ tumor vaccination. Front Immunol. 2017;8:229.CrossRef Wennerberg E, Lhuillier C, Vanpouille-Box C, Pilones KA, García-Martínez E, et al. Barriers to radiation-induced in situ tumor vaccination. Front Immunol. 2017;8:229.CrossRef
10.
Zurück zum Zitat Bröckelmann PJ, Borchmann P, Engert A. Current and future immunotherapeutic approaches in Hodgkin Lymphoma. Leukemia Lymphoma. 2016;57(9):2014–24.CrossRef Bröckelmann PJ, Borchmann P, Engert A. Current and future immunotherapeutic approaches in Hodgkin Lymphoma. Leukemia Lymphoma. 2016;57(9):2014–24.CrossRef
11.
Zurück zum Zitat Barth MJ, Chu Y, Hanley PJ, et al. Immunotherapeutic approaches for the treatment of childhood, adolescent and Young adult non-Hodgkin Lymphoma. Br J Haematol. 2016;173:597–616.CrossRef Barth MJ, Chu Y, Hanley PJ, et al. Immunotherapeutic approaches for the treatment of childhood, adolescent and Young adult non-Hodgkin Lymphoma. Br J Haematol. 2016;173:597–616.CrossRef
12.
Zurück zum Zitat Brody JD, Ai WZ, Czerwinski DK, et al. In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. J Clin Oncol. 2010;28(28):4324–32.CrossRef Brody JD, Ai WZ, Czerwinski DK, et al. In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. J Clin Oncol. 2010;28(28):4324–32.CrossRef
13.
Zurück zum Zitat Michot JM, Mazeron R, Dercle L, et al. Abscopal effect in a Hodgkin lymphoma patient treated by anti-programmed death 1 antibody. Eur J Can. 2016;66:91–4.CrossRef Michot JM, Mazeron R, Dercle L, et al. Abscopal effect in a Hodgkin lymphoma patient treated by anti-programmed death 1 antibody. Eur J Can. 2016;66:91–4.CrossRef
14.
Zurück zum Zitat Qin Q, Nan X, Miller T, Fisher R, Teh B, et al. Complete local and abscopal responses from a combination of radiation and Nivolumab in refractory Hodgkin’s Lymphoma. Radiat Res. 2018;190(3):322–9.CrossRef Qin Q, Nan X, Miller T, Fisher R, Teh B, et al. Complete local and abscopal responses from a combination of radiation and Nivolumab in refractory Hodgkin’s Lymphoma. Radiat Res. 2018;190(3):322–9.CrossRef
15.
Zurück zum Zitat Li J, Song W, Czerwinski DK, Varghese B, et al. Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself. J Immunol. 2007;179:2493–500.CrossRef Li J, Song W, Czerwinski DK, Varghese B, et al. Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself. J Immunol. 2007;179:2493–500.CrossRef
16.
Zurück zum Zitat Dovedi SJ, Melis MH, Wilkinson RW, Adlard AL, Stratford IJ, et al. Systemic delivery of a TLR7 agonist in combination with radiation primes durable antitumor immune responses in mouse models of lymphoma. Blood. 2013;121(2):251–9.CrossRef Dovedi SJ, Melis MH, Wilkinson RW, Adlard AL, Stratford IJ, et al. Systemic delivery of a TLR7 agonist in combination with radiation primes durable antitumor immune responses in mouse models of lymphoma. Blood. 2013;121(2):251–9.CrossRef
17.
Zurück zum Zitat Lu H, Ford E, Schwartz JL, Hewitt J, Hsu FJ, et al. Intratumoral G100 rescues radiation-induced T cell depletion and has synergistic anti-tumor effect with local irradiation in A20 lymphoma. Blood. 2016;128:4166. Lu H, Ford E, Schwartz JL, Hewitt J, Hsu FJ, et al. Intratumoral G100 rescues radiation-induced T cell depletion and has synergistic anti-tumor effect with local irradiation in A20 lymphoma. Blood. 2016;128:4166.
18.
Zurück zum Zitat Deng L, Liang H, Burnette B, et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumour immunity in mice. J Clin Invest. 2014;124:687–95.CrossRef Deng L, Liang H, Burnette B, et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumour immunity in mice. J Clin Invest. 2014;124:687–95.CrossRef
19.
Zurück zum Zitat Bremnes RM, Busund LT, Kilvær TL, et al. The role of tumor-infiltrating lymphocytes in development, progression, and prognosis of non-small cell lung cancer. J Thorac Oncol. 2016;11:789–800.CrossRef Bremnes RM, Busund LT, Kilvær TL, et al. The role of tumor-infiltrating lymphocytes in development, progression, and prognosis of non-small cell lung cancer. J Thorac Oncol. 2016;11:789–800.CrossRef
20.
Zurück zum Zitat Brambilla E, Le Teuff G, Marguet S, et al. Prognostic effect of tumor lymphocytic infiltration in resectable non-small-cell lung cancer. J Clin Oncol. 2016;34:1223–30.CrossRef Brambilla E, Le Teuff G, Marguet S, et al. Prognostic effect of tumor lymphocytic infiltration in resectable non-small-cell lung cancer. J Clin Oncol. 2016;34:1223–30.CrossRef
21.
Zurück zum Zitat Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348:124–8.CrossRef Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348:124–8.CrossRef
22.
Zurück zum Zitat Gettinger SN, Horn L, Gandhi L, Spigel DR, Antonia SJ, et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol. 2015;33(18):2004–12.CrossRef Gettinger SN, Horn L, Gandhi L, Spigel DR, Antonia SJ, et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol. 2015;33(18):2004–12.CrossRef
23.
Zurück zum Zitat Villanueva N, Bazhenova L. New strategies in immunotherapy for lung cancer: beyond PD-1/PD-L1. Ther Adv Respir Dis. 2018;12:1753466618794133.CrossRef Villanueva N, Bazhenova L. New strategies in immunotherapy for lung cancer: beyond PD-1/PD-L1. Ther Adv Respir Dis. 2018;12:1753466618794133.CrossRef
24.
Zurück zum Zitat Shaverdian N, Lisberg AE, Bornazyan K, Veruttipong D, Goldman JW, Formenti SC, et al. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol. 2017;18(7):895–903.CrossRef Shaverdian N, Lisberg AE, Bornazyan K, Veruttipong D, Goldman JW, Formenti SC, et al. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol. 2017;18(7):895–903.CrossRef
25.
Zurück zum Zitat Golden EB, Chhabra A, Chachoua A, Adams S, Donach M, et al. Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial. Lancet Oncol. 2015;16(7):795–803.CrossRef Golden EB, Chhabra A, Chachoua A, Adams S, Donach M, et al. Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial. Lancet Oncol. 2015;16(7):795–803.CrossRef
26.
Zurück zum Zitat von Reibnitz D, Chaft JE, Wu AJ, Samstein R, Hellmann MD, Plodkowski AJ, et al. Safety of combining thoracic radiation therapy with concurrent versus sequential immune checkpoint inhibition. Adv Radiat Oncol. 2018;3(3):391–8.CrossRef von Reibnitz D, Chaft JE, Wu AJ, Samstein R, Hellmann MD, Plodkowski AJ, et al. Safety of combining thoracic radiation therapy with concurrent versus sequential immune checkpoint inhibition. Adv Radiat Oncol. 2018;3(3):391–8.CrossRef
27.
Zurück zum Zitat Golden EB, Demaria S, Schiff PB, Chachoua A, Formenti SC. An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. Cancer Immunol Res. 2013;1(6):365–72.CrossRef Golden EB, Demaria S, Schiff PB, Chachoua A, Formenti SC. An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. Cancer Immunol Res. 2013;1(6):365–72.CrossRef
29.
Zurück zum Zitat Van den Heuvel MM, Verheij M, Boshuizen R, Belderbos J, Dingemans AM, De Ruysscher D, et al. NHS-IL2 combined with radiotherapy: preclinical rationale and phase Ib trial results in metastatic non-small cell lung cancer following first-line chemotherapy. J Transl Med. 2015;27(13):32.CrossRef Van den Heuvel MM, Verheij M, Boshuizen R, Belderbos J, Dingemans AM, De Ruysscher D, et al. NHS-IL2 combined with radiotherapy: preclinical rationale and phase Ib trial results in metastatic non-small cell lung cancer following first-line chemotherapy. J Transl Med. 2015;27(13):32.CrossRef
30.
Zurück zum Zitat SJ Antonia, A. Villegas, D. Daniel, D. Vicente, S. Murakami, R. Hui et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. SJ Antonia, A. Villegas, D. Daniel, D. Vicente, S. Murakami, R. Hui et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC.
31.
Zurück zum Zitat Hao Y, Yasmin-Karim S, Moreau M, Sinha N, Sajo E, Ngwa W. Enhancing radiotherapy for lung cancer using immunoadjuvants delivered in situ from new design radiotherapy biomaterials: a preclinical study. Phys Med Biol. 2016;61(24):N697–707.CrossRef Hao Y, Yasmin-Karim S, Moreau M, Sinha N, Sajo E, Ngwa W. Enhancing radiotherapy for lung cancer using immunoadjuvants delivered in situ from new design radiotherapy biomaterials: a preclinical study. Phys Med Biol. 2016;61(24):N697–707.CrossRef
32.
Zurück zum Zitat Flynn JP, O’Hara MH, Gandhi SJ. Preclinical rationale for combining radiation therapy and immunotherapy beyond checkpoint inhibitors (i.e., CART). Transl Lung Cancer Res. 2017;6(2):159–68.CrossRef Flynn JP, O’Hara MH, Gandhi SJ. Preclinical rationale for combining radiation therapy and immunotherapy beyond checkpoint inhibitors (i.e., CART). Transl Lung Cancer Res. 2017;6(2):159–68.CrossRef
33.
Zurück zum Zitat Zhang H, Liu L, Yu D, Kandimalla ER, Sun HB, Agrawal S, Guha C. An in situ autologous tumor vaccination with combined radiation therapy and TLR9 agonist therapy. PLoS ONE. 2012;7(5):e38111.CrossRef Zhang H, Liu L, Yu D, Kandimalla ER, Sun HB, Agrawal S, Guha C. An in situ autologous tumor vaccination with combined radiation therapy and TLR9 agonist therapy. PLoS ONE. 2012;7(5):e38111.CrossRef
34.
Zurück zum Zitat Porta C, Chiellino S, Ferrari A, Mariucci S, Liguigli W, et al. Pharmacotherapy for treating metastatic clear cell renal cell carcinoma. Expert Opin Pharmacother. 2017;18(2):205–16.CrossRef Porta C, Chiellino S, Ferrari A, Mariucci S, Liguigli W, et al. Pharmacotherapy for treating metastatic clear cell renal cell carcinoma. Expert Opin Pharmacother. 2017;18(2):205–16.CrossRef
35.
Zurück zum Zitat Beaumont JL, Salsman JM, Diaz J, Deen KC, McCann L, Powles T, et al. Quality-adjusted time without symptoms or toxicity analysis of pazopanib versus sunitinib in patients with renal cell carcinoma. Cancer. 2016;122(7):1108–15.CrossRef Beaumont JL, Salsman JM, Diaz J, Deen KC, McCann L, Powles T, et al. Quality-adjusted time without symptoms or toxicity analysis of pazopanib versus sunitinib in patients with renal cell carcinoma. Cancer. 2016;122(7):1108–15.CrossRef
36.
Zurück zum Zitat MacManus MP, Harte RJ, Stranex S. Spontaneous regression of metastatic renal cell carcinoma following palliative irradiation of the primary tumour. Ir J Med Sci. 1994;163(10):461–3.CrossRef MacManus MP, Harte RJ, Stranex S. Spontaneous regression of metastatic renal cell carcinoma following palliative irradiation of the primary tumour. Ir J Med Sci. 1994;163(10):461–3.CrossRef
37.
Zurück zum Zitat Ishiyama H, Teh BS, Ren H, Chiang S, Tann A, Blanco AI, Paulino AC, Amato R, et al. Spontaneous regression of thoracic metastases while progression of brain metastases after stereotactic radiosurgery and stereotactic body radiotherapy for metastatic renal cell carcinoma: abscopal effect prevented by the blood-brain barrier? Clin Genitourin Cancer. 2012;10(3):196–8.CrossRef Ishiyama H, Teh BS, Ren H, Chiang S, Tann A, Blanco AI, Paulino AC, Amato R, et al. Spontaneous regression of thoracic metastases while progression of brain metastases after stereotactic radiosurgery and stereotactic body radiotherapy for metastatic renal cell carcinoma: abscopal effect prevented by the blood-brain barrier? Clin Genitourin Cancer. 2012;10(3):196–8.CrossRef
38.
Zurück zum Zitat Buttigliero C, Allis S, Tucci M, Zichi C, Leone G, Di Stefano RF, et al. Role of radiotherapy in improving activity of immune-modulating drugs in advanced renal cancer: biological rationale and clinical evidences. Cancer Treat Rev. 2018;69:215–23.CrossRef Buttigliero C, Allis S, Tucci M, Zichi C, Leone G, Di Stefano RF, et al. Role of radiotherapy in improving activity of immune-modulating drugs in advanced renal cancer: biological rationale and clinical evidences. Cancer Treat Rev. 2018;69:215–23.CrossRef
39.
Zurück zum Zitat Ridolfi L, de Rosa F, Ridolfi R, Gentili G, Valmorri L, Scarpi E, et al. Radiotherapy as an immunological booster in patients with metastatic melanoma or renal cell carcinoma treated with high-dose Interleukin-2: evaluation of biomarkers of immunologic and therapeutic response. J Transl Med. 2014;23(12):262.CrossRef Ridolfi L, de Rosa F, Ridolfi R, Gentili G, Valmorri L, Scarpi E, et al. Radiotherapy as an immunological booster in patients with metastatic melanoma or renal cell carcinoma treated with high-dose Interleukin-2: evaluation of biomarkers of immunologic and therapeutic response. J Transl Med. 2014;23(12):262.CrossRef
40.
Zurück zum Zitat Seung SK, Curti BD, Crittenden M, Walker E, Coffey T, Siebert JC, et al. Phase 1 study of stereotactic body radiotherapy and interleukin-2—tumor and immunological responses. Sci Transl Med. 2012;4(137):137ra74.CrossRef Seung SK, Curti BD, Crittenden M, Walker E, Coffey T, Siebert JC, et al. Phase 1 study of stereotactic body radiotherapy and interleukin-2—tumor and immunological responses. Sci Transl Med. 2012;4(137):137ra74.CrossRef
41.
Zurück zum Zitat Merriman J, Tward J, Albertson D, Dechet C, Agarwal N, et al. Durable response to treatment with combination radiotherapy and high-dose interleukin-2 in metastatic chromophobe variant renal cell carcinoma. J Immunother. 2016;39(2):101–3.CrossRef Merriman J, Tward J, Albertson D, Dechet C, Agarwal N, et al. Durable response to treatment with combination radiotherapy and high-dose interleukin-2 in metastatic chromophobe variant renal cell carcinoma. J Immunother. 2016;39(2):101–3.CrossRef
42.
Zurück zum Zitat Park SS, Dong H, Liu X, Harrington SM, Krco CJ, Grams MP, et al. PD-1 restrains radiotherapy-induced abscopal effect. Cancer Immunol Res. 2015;3(6):610–9.CrossRef Park SS, Dong H, Liu X, Harrington SM, Krco CJ, Grams MP, et al. PD-1 restrains radiotherapy-induced abscopal effect. Cancer Immunol Res. 2015;3(6):610–9.CrossRef
43.
Zurück zum Zitat Fridman WH, Zitvogel L, Sautès-Fridman C, Kroemer G. The immune contexture in cancer prognosis and treatment. Nat Rev Clin Oncol. 2017;14(12):717–34.CrossRef Fridman WH, Zitvogel L, Sautès-Fridman C, Kroemer G. The immune contexture in cancer prognosis and treatment. Nat Rev Clin Oncol. 2017;14(12):717–34.CrossRef
44.
Zurück zum Zitat Ock CY, Keam B, Kim S, Lee JS, Kim M, Kim TM, et al. Pan-cancer immunogenomic perspective on the tumor microenvironment based on PD-L1 and CD8 T-cell infiltration. Clin Cancer Res. 2016;22(9):2261–70.CrossRef Ock CY, Keam B, Kim S, Lee JS, Kim M, Kim TM, et al. Pan-cancer immunogenomic perspective on the tumor microenvironment based on PD-L1 and CD8 T-cell infiltration. Clin Cancer Res. 2016;22(9):2261–70.CrossRef
45.
Zurück zum Zitat Economopoulou F, Agelaki S, et al. The promise of immunotherapy in head and neck squamous cell carcinoma. Ann Oncol. 2016;27(9):1675–85.CrossRef Economopoulou F, Agelaki S, et al. The promise of immunotherapy in head and neck squamous cell carcinoma. Ann Oncol. 2016;27(9):1675–85.CrossRef
46.
Zurück zum Zitat Mandal R, et al. The head and neck cancer immune landscape and its immunotherapeutic implications. JCI Insight. 2016;1(17):e89829.CrossRef Mandal R, et al. The head and neck cancer immune landscape and its immunotherapeutic implications. JCI Insight. 2016;1(17):e89829.CrossRef
48.
Zurück zum Zitat Kono Koji, Mimura Kousaku. Immunogenic tumor cell death induced by chemoradiotherapy in a clinical setting. Oncoimmunology. 2013;2(1):e22197.CrossRef Kono Koji, Mimura Kousaku. Immunogenic tumor cell death induced by chemoradiotherapy in a clinical setting. Oncoimmunology. 2013;2(1):e22197.CrossRef
49.
Zurück zum Zitat Turajlic S, Gore M, Larkin J. First report of overall survival for ipilimumab plus nivolumab from the phase III Checkmate 067 study in advanced melanoma. Ann Oncol. 2018;29(3):542–3.CrossRef Turajlic S, Gore M, Larkin J. First report of overall survival for ipilimumab plus nivolumab from the phase III Checkmate 067 study in advanced melanoma. Ann Oncol. 2018;29(3):542–3.CrossRef
50.
Zurück zum Zitat Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med. 2012;366:925–31.CrossRef Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med. 2012;366:925–31.CrossRef
51.
Zurück zum Zitat Stamell EF, Wolchok JD, Gnjatic Sacha, Lee NY, Brownell I. The abscopal effect associated with a systemic anti-melanoma immune response. Int J Radiat Oncol Biol Phys. 2013;85(2):293–5.CrossRef Stamell EF, Wolchok JD, Gnjatic Sacha, Lee NY, Brownell I. The abscopal effect associated with a systemic anti-melanoma immune response. Int J Radiat Oncol Biol Phys. 2013;85(2):293–5.CrossRef
52.
Zurück zum Zitat Knisely JP, Yu JB, Flanigan J, Sznol M, Kluger HM, Chiang VL. Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival. J Neurosurg. 2012;117(2):227–33.CrossRef Knisely JP, Yu JB, Flanigan J, Sznol M, Kluger HM, Chiang VL. Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival. J Neurosurg. 2012;117(2):227–33.CrossRef
53.
Zurück zum Zitat Silk AW, Bassetti MF, West BT, Tsien CI, Lao CD. Ipilimumab and radiation therapy for melanoma brain metastases. Cancer Med. 2013;2(6):899–906.CrossRef Silk AW, Bassetti MF, West BT, Tsien CI, Lao CD. Ipilimumab and radiation therapy for melanoma brain metastases. Cancer Med. 2013;2(6):899–906.CrossRef
54.
Zurück zum Zitat Kiess AP, Wolchok JD, Barker CA, Postow MA, Tabar V, Huse JT, et al. Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment. Int J Radiat Oncol Biol Phys. 2015;92(2):368–75.CrossRef Kiess AP, Wolchok JD, Barker CA, Postow MA, Tabar V, Huse JT, et al. Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment. Int J Radiat Oncol Biol Phys. 2015;92(2):368–75.CrossRef
55.
Zurück zum Zitat Grimaldi AM, Simeone E, Giannarelli D, Muto P, Falivene S, Borzillo V, et al. Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy. Oncoimmunology. 2014;14(3):e28780.CrossRef Grimaldi AM, Simeone E, Giannarelli D, Muto P, Falivene S, Borzillo V, et al. Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy. Oncoimmunology. 2014;14(3):e28780.CrossRef
56.
Zurück zum Zitat Ahmed KA, Stallworth DG, Kim Y, Johnstone PA, Harrison LB, Caudell JJ, et al. Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy. Ann Oncol. 2016;27(3):434–41.CrossRef Ahmed KA, Stallworth DG, Kim Y, Johnstone PA, Harrison LB, Caudell JJ, et al. Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy. Ann Oncol. 2016;27(3):434–41.CrossRef
57.
Zurück zum Zitat Park SS, Dong H, Liu X, et al. PD-1 restrains radiotherapy-induced abscopal effect. Cancer Immunol Res. 2015;3:610–9.CrossRef Park SS, Dong H, Liu X, et al. PD-1 restrains radiotherapy-induced abscopal effect. Cancer Immunol Res. 2015;3:610–9.CrossRef
58.
Zurück zum Zitat Lugade AA, Moran JP, Gerber SA, Rose RC, Frelinger JG, Lord EM. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J Immunol. 2005;174(12):7516–23.CrossRef Lugade AA, Moran JP, Gerber SA, Rose RC, Frelinger JG, Lord EM. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J Immunol. 2005;174(12):7516–23.CrossRef
59.
Zurück zum Zitat Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, et al. Radiation and dual checkpoint blockade activates non-redundant immune mechanisms in cancer. Nature. 2015;520(7547):373–7.CrossRef Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, et al. Radiation and dual checkpoint blockade activates non-redundant immune mechanisms in cancer. Nature. 2015;520(7547):373–7.CrossRef
60.
Zurück zum Zitat Schaue D, Ratikan JA, Iwamoto KS, McBride WH. Maximizing tumor immunity with fractionated radiation. Int J Radiat Oncol Biol Phys. 2012;83(4):1306–10.CrossRef Schaue D, Ratikan JA, Iwamoto KS, McBride WH. Maximizing tumor immunity with fractionated radiation. Int J Radiat Oncol Biol Phys. 2012;83(4):1306–10.CrossRef
61.
Zurück zum Zitat Lee S, Son B, Park G, Kim H, Kang H, Jeon J, et al. The dual role of NK cells in antitumor reactions triggered by ionizing radiation in combination with hyperthermia. Int J Mol Sci. 2018;19(9):2795.CrossRef Lee S, Son B, Park G, Kim H, Kang H, Jeon J, et al. The dual role of NK cells in antitumor reactions triggered by ionizing radiation in combination with hyperthermia. Int J Mol Sci. 2018;19(9):2795.CrossRef
Metadaten
Titel
Time for radioimmunotherapy: an overview to bring improvements in clinical practice
verfasst von
O. Leaman Alcibar
D. Candini
F. López-Campos
M. Albert Antequera
V. Morillo Macías
A. J. Conde
A. Rodríguez Pérez
A. Hervás Morón
J. Contreras Martínez
C. Ferrer Albiach
S. Navarro Aguilar
M. E. Rodríguez-Ruiz
Publikationsdatum
14.01.2019
Verlag
Springer International Publishing
Erschienen in
Clinical and Translational Oncology / Ausgabe 8/2019
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-018-02027-1

Weitere Artikel der Ausgabe 8/2019

Clinical and Translational Oncology 8/2019 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.